NEO-CONCEPT INTL GROUP HLD-A
NCINASDAQTrading Snapshot
- Day Range
- $3.71 β $4.09
- 52-Week Range
- $2.00 β $883.84
- Volume (shares)
- 6,271
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.0M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $137M
- Last Q Revenue
- $56M
- P/E Ratio
- -0.7
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-39.77
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β80.0%
NEO-CONCEPT INTL GROUP HLD-A
NCIAbout NEO-CONCEPT INTL GROUP HLD-A
Neo-Concept International Group Holdings Limited, established in 2021 and headquartered in Kwun Tong, Hong Kong, operates as a comprehensive provider of apparel solutions. This subsidiary of Neo-concept (BVI) Limited offers a wide spectrum of services throughout the clothing supply chain. These services include analyzing market trends, designing and developing products, procuring raw materials, overseeing production and quality assurance, and managing logistics. Furthermore, the company sells knitwear and other garments under its "les 100 ciels" label. Its primary customer base comprises brand owners, clothing sourcing agencies, and online fashion retailers, mainly situated in North America, the United Kingdom, and across Europe.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium
REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maxi

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months

Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
SAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (βOlema,β Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (βAcrivonβ or βAcrivon Therapeuticsβ) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines u

Neo-Concept International Announces Share Consolidation
HONG KONG, Nov. 02, 2026 (GLOBE NEWSWIRE) -- On October 29, 2026, Neo-Concept International Group Holdings Ltd (the βCompanyβ) held the Company's Extraordinary General Meeting (the βEGMβ) , amongst which a share consolid

Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-